Literature DB >> 3896964

Effect of (+)-cyanidanol-3 on chronic active hepatitis: a double blind controlled trial.

S Bar-Meir, Z Halpern, M Gutman, Z Shpirer, M Baratz, D Bass.   

Abstract

Forty patients with biopsy proven chronic active hepatitis were studied, 22 received (+)-cyanidanol-3 in a dose of 3 g daily and 18 placebo. Side effects related to cyanidanol were fever (four patients), haemolysis (one patient) and urticaria (one patient). All side effects subsided on discontinuation of the medication. Cyanidanol had an effect no better than placebo on symptoms, laboratory tests, and histological findings on liver biopsy.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3896964      PMCID： PMC1432867          DOI： 10.1136/gut.26.9.975

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  4 in total

1.  The effect of (+)-catechin on the hepatic level of ATP and the lipid content of liver during experimental steatosis.

Authors:  A Gajdos; M Gajdos-Tërök; R Horn
Journal:  Biochem Pharmacol       Date:  1972-02-15       Impact factor: 5.858

2.  Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis.

Authors:  R D Soloway; W H Summerskill; A H Baggenstoss; M G Geall; G L Gitnićk; I R Elveback; L J Schoenfield
Journal:  Gastroenterology       Date:  1972-11       Impact factor: 22.682

3.  (+)-Cyanidanol-3 in the treatment of acute viral hepatitis: a randomized controlled trial.

Authors:  H Schomerus; K H Wiedmann; W Dölle; H Peerenboom; G Strohmeyer; K Balzer; H Goebell; H K Dürr; C Bode; A L Blum
Journal:  Hepatology       Date:  1984 Mar-Apr       Impact factor: 17.425

4.  Treatment of acute viral hepatitis with (+)-cyanidanol-3.

Authors:  A L Blum; P Berthet; W Doelle; H Goebell; K Kortüm; S Pelloni; P Peter; H Poulsen; G Strohmeyer; N Tygstrup
Journal:  Lancet       Date:  1977-12-03       Impact factor: 79.321
  4 in total
  2 in total

Review 1.  Historical treatment of chronic hepatitis B and chronic hepatitis C.

Authors:  P Ferenci
Journal:  Gut       Date:  1993       Impact factor: 23.059

2.  Trial of (+)-cyanidanol-3 in patients with hepatitis B chronic liver disease.

Authors:  P W Keeling; L Viola; M G Anderson; J H Marigold; J C Macartney; F J Paradinas; I M Murray-Lyon; R P Thompson
Journal:  J R Soc Med       Date:  1986-08       Impact factor: 5.344
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.